# Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

> **NCT00378521** · PHASE2 · COMPLETED · sponsor: **MediQuest Therapeutics** · enrollment: 15 (estimated)

## Conditions studied

- Raynaud's Disease
- Raynaud's Disease Secondary to Scleroderma
- Raynaud's Disease Secondary to Autoimmune Disease

## Interventions

- **DRUG:** MQX-503

## Key facts

- **NCT ID:** NCT00378521
- **Lead sponsor:** MediQuest Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2007-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378521, "Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00378521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*